Xenon Pharmaceuticals Inc. (XENE)

Market Cap	2.44B
Revenue (ttm)	7.50M
Net Income (ttm)	-251.45M
Shares Out	76.73M
EPS (ttm)	-3.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,404,953
Open	32.08
Previous Close	32.17
Day's Range	31.54 - 32.37
52-Week Range	26.74 - 46.00
Beta	1.10
Analysts	Strong Buy
Price Target	54.82 (+72.61%)
Earnings Date	Aug 7, 2025

About XENE

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2014
• Employees: 327
• Stock Exchange: NASDAQ
• Ticker Symbol: XENE
• Website: https://www.xenon-pharma.com

Analyst Forecast

According to 11 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price forecast is $54.82, which is an increase of 72.61% from the latest price.

Price Target

$54.82

(72.61% upside)

Analyst Consensus: Strong Buy